Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,018,645
  • Shares Outstanding, K 44,441
  • Annual Sales, $ 1,449 M
  • Annual Income, $ -104,500 K
  • 60-Month Beta 0.54
  • Price/Sales 4.23
  • Price/Cash Flow N/A
  • Price/Book 1.84
Trade UTHR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 3.18
  • Number of Estimates 4
  • High Estimate 3.58
  • Low Estimate 2.95
  • Prior Year 1.20
  • Growth Rate Est. (year over year) +165.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.76 +11.85%
on 10/26/20
144.26 -6.37%
on 11/16/20
+12.29 (+10.01%)
since 10/23/20
3-Month
98.37 +37.31%
on 09/24/20
144.26 -6.37%
on 11/16/20
+30.02 (+28.58%)
since 08/25/20
52-Week
75.58 +78.71%
on 03/18/20
144.26 -6.37%
on 11/16/20
+39.73 (+41.67%)
since 11/25/19

Most Recent Stories

More News
United Therapeutics Releases Its First Corporate Responsibility Report

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the release of its initial Corporate Responsibility Report with primarily 2019 data and selected 2020 highlights,...

UTHR : 135.07 (-0.27%)
MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics

MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and...

UTHR : 135.07 (-0.27%)
MNKD : 2.95 (-3.59%)
United Therapeut Has Returned 30.6% Since SmarTrend Recommendation (UTHR)

SmarTrend identified an Uptrend for United Therapeut (NASDAQ:UTHR) on October 14th, 2020 at $109.41. In approximately 1 month, United Therapeut has returned 30.63% as of today's recent price of $142.92....

UTHR : 135.07 (-0.27%)
3 Biotech Stocks Set to Soar in 2021

As Pfizer (PFE) announced that its COVID-19 vaccine candidate is 90% effective, biotech stocks are on fire. These stocks have seen a bull-run since the beginning of 2020 and are expected to witness the...

JAZZ : 141.83 (-0.70%)
ARWR : 57.02 (-5.58%)
UTHR : 135.07 (-0.27%)
NTLA : 35.86 (+3.02%)
United Therapeutics Corporation To Present At The Jefferies Virtual London Healthcare Conference

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. , Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the...

UTHR : 135.07 (-0.27%)
Shares of UTHR Up 25.3% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for United Therapeut (NASDAQ:UTHR) on October 14th, 2020 at $109.41. In approximately 3 weeks, United Therapeut has returned 25.28% as of today's recent price of $137.07....

UTHR : 135.07 (-0.27%)
Hypertension Drugs Market Analysis, Revenue, Price, Market Share, Growth Rate, Forecast to 2025

Selbyville, Delaware, Market Study Report LLC delivers significant information and realistic data of the Global Hypertension Drugs Market via this newly added research in its database. The report presents...

ALIOF : 278.5000 (unch)
AZN : 52.60 (-1.81%)
DSNKY : 35.6300 (+0.65%)
MRK : 80.06 (-0.10%)
NVS : 89.18 (+1.00%)
PFE : 36.53 (-0.19%)
UTHR : 135.07 (-0.27%)
VRX.TO : 30.80 (-3.33%)
United Therapeutics Corporation To Present At The Credit Suisse 29th Annual Virtual Healthcare Conference

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. , President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the...

UTHR : 135.07 (-0.27%)
United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

MDT : 113.31 (-0.66%)
LLY : 144.75 (-0.10%)
UTHR : 135.07 (-0.27%)
CTLT : 94.65 (-0.01%)
United Therapeutics (UTHR) Q3 Earnings and Revenues Surpass Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 59.34% and 5.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

UTHR : 135.07 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability....

See More

Key Turning Points

2nd Resistance Point 139.08
1st Resistance Point 137.08
Last Price 135.07
1st Support Level 133.99
2nd Support Level 132.90

See More

52-Week High 144.26
Last Price 135.07
Fibonacci 61.8% 118.02
Fibonacci 50% 109.92
Fibonacci 38.2% 101.82
52-Week Low 75.58

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar